Current Allergy and Asthma Reports

, Volume 12, Issue 3, pp 246–254 | Cite as

Treatment Update in Multiple Sclerosis



Multiple sclerosis is the most common cause of disability in young people in the Western world. Reduced life expectancy and worsening quality of life due to increasing disability later in the disease course have significant personal and societal costs. Changes in treatment strategies and newly available treatments hope to improve the outlook for our often young patients. This paper details currently available treatments and some that are expected to reach the market shortly.


Multiple sclerosis Treatment Algorithm Interferon-beta Glatiramer acetate Natalizumab Mitoxantrone Fingolimod Dimethyl fumarate Cladribine Alemtuzumab Rituximab 



Dr. Morris has had travel/accommodations expenses covered/reimbursed by UCB.

Dr. Yiannikas has received grant support from Biogen Idec and Novartis; has received honoraria for giving lectures from Biogen Idec and Novartis; and has had travel/accommodations expenses covered/reimbursed by Biogen Idec, Novartis, and Sanofi Aventis.


Papers of particular interest, published recently, have been highlighted as • Of importance •• Of major important

  1. 1.
    Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med. 2012;366(4):339–47.PubMedCrossRefGoogle Scholar
  2. 2.
    Miller DH, Hammond SR, McLeod JG, Purdie G, Skegg DC. Multiple sclerosis in Australia and New Zealand: are the determinants genetic or environmental? J Neurol Neurosurg Psychiatry. 1990;53(10):903–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010;9(7):727–39.PubMedCrossRefGoogle Scholar
  4. 4.
    Frohman EM, Racke MK, Raine CS. Multiple sclerosis–the plaque and its pathogenesis. N Engl J Med. 2006;354(9):942–55.PubMedCrossRefGoogle Scholar
  5. 5.
    Aktas O, Kieseier B, Hartung HP. Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends Neurosci. 2010;33(3):140–52.PubMedCrossRefGoogle Scholar
  6. 6.
    • Howell ORN, Nicholas R, Carassiti D, Roncaroli F, Magliozzi R, Aloisi F, et al. Oral Presentation 105 in Abstracts of the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. October 19–22, 2011. Amsterdam, The Netherlands. Mult Scler. 2011;17(10 Suppl):S9–524. This describes nodules of inflammation sequestered in the meninges, which may be a locus for the chronic immunomodulation–resistant progressive phase of the disease.CrossRefGoogle Scholar
  7. 7.
    Kieseier BC, Stuve O. A critical appraisal of treatment decisions in multiple sclerosis–old versus new. Nat Rev Neurol. 2011;7(5):255–62.PubMedCrossRefGoogle Scholar
  8. 8.
    Kinkel RP, Kollman C, O’Connor P, Murray TJ, Simon J, Arnold D, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006;66(5):678–84.PubMedCrossRefGoogle Scholar
  9. 9.
    Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374(9700):1503–11.PubMedCrossRefGoogle Scholar
  10. 10.
    Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet. 2001;357(9268):1576–82.PubMedCrossRefGoogle Scholar
  11. 11.
    Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9444):1489–96.PubMedCrossRefGoogle Scholar
  12. 12.
    Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009;8(11):987–97.PubMedCrossRefGoogle Scholar
  13. 13.
    • Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, et al. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(3):282–7. This article provides long-term follow-up data with regard to early versus delayed treatment initiation and early indicators of disease course.PubMedCrossRefGoogle Scholar
  14. 14.
    Goodin DS. Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology. 2008;71(24 Suppl 3):S8–13.PubMedCrossRefGoogle Scholar
  15. 15.
    Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–52.PubMedGoogle Scholar
  16. 16.
    Pozzilli C, Prosperini L. Clinical markers of therapeutic response to disease modifying drugs. Neurol Sci. 2008;29 Suppl 2:S211–3.PubMedCrossRefGoogle Scholar
  17. 17.
    Hartung HP, Aktas O. Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria. Lancet Neurol. 2011;10(4):293–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Giovannoni G. Multiple sclerosis cerebrospinal fluid biomarkers. Dis Markers. 2006;22(4):187–96.PubMedGoogle Scholar
  19. 19.
    Mikol DD, Barkhof F, Chang P, Coyle PK, Jeffery DR, Schwid SR, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol. 2008;7(10):903–14.PubMedCrossRefGoogle Scholar
  20. 20.
    O’Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009;8(10):889–97.PubMedCrossRefGoogle Scholar
  21. 21.
    Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.PubMedCrossRefGoogle Scholar
  22. 22.
    • Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009;8(3):254–60. This was the first group to describe a combined radiological and clinical outcome parameter to guide future trial design and retrospective analysis.PubMedCrossRefGoogle Scholar
  23. 23.
    Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911–23.PubMedCrossRefGoogle Scholar
  24. 24.
    Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009;72(9):806–12.PubMedCrossRefGoogle Scholar
  25. 25.
    •• Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011;10(8):745–58. PML risk stratification is essential in informing treatment decision making in patients with active disease. This article presents the data and an algorithm to assist treatment plans.PubMedCrossRefGoogle Scholar
  26. 26.
    Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68(3):295–303.PubMedCrossRefGoogle Scholar
  27. 27.
    •• Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401. This was the trial that led to marketing of the first oral therapy available for multiple sclerosis treatment.PubMedCrossRefGoogle Scholar
  28. 28.
    Conway D, Cohen JA. Emerging oral therapies in multiple sclerosis. Curr Neurol Neurosci Rep. 2010;10(5):381–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–15.PubMedCrossRefGoogle Scholar
  30. 30.
    • Lindsey J, Haden-Pinneri K, Memon N, Buja L. Sudden unexpected death on fingolimod. Mult Scler. 2012 Feb 2. Concerns around cardiac death in fingolimod are emerging, and this is the first published information on a case. Google Scholar
  31. 31.
    Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008;359(17):1786–801.PubMedCrossRefGoogle Scholar
  32. 32.
    Boggild M. Immunosuppression followed by immunomodulation. J Neurol Sci. 2009;277 Suppl 1:S50–4.PubMedCrossRefGoogle Scholar
  33. 33.
    • Martinelli V, Cocco E, Capra R, Salemi G, Gallo P, Capobianco M, et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology. 2011;77(21):1887–95. Mitoxantrone is still used in some countries. This paper describes that the risk of hematologic malignancies may be more common and for longer than previously realized.PubMedCrossRefGoogle Scholar
  34. 34.
    Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003;61(10):1332–8.PubMedGoogle Scholar
  35. 35.
    Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358(7):676–88.PubMedCrossRefGoogle Scholar
  36. 36.
    • Killestein J, Rudick RA, Polman CH. Oral treatment for multiple sclerosis. Lancet Neurol. 2011;10(11):1026–34. This article provides further discussion of the issues around deciding to use oral agents in treatment of multiple sclerosis.PubMedCrossRefGoogle Scholar
  37. 37.
    Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416–26.PubMedCrossRefGoogle Scholar
  38. 38.
    Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sorensen PS, Vermersch P, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011;10(4):329–37.PubMedCrossRefGoogle Scholar
  39. 39.
    • O’Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293–303. This provides information on a potential new oral agent for treatment of multiple sclerosis.PubMedCrossRefGoogle Scholar
  40. 40.
    Confavreux C, Li DK, Freedman MS, Truffinet P, Benzerdjeb H, Wang D, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler. 2012 Feb 7.Google Scholar
  41. 41.
    Kappos L, Gold R, Miller DH, Macmanus DG, Havrdova E, Limmroth V, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008;372(9648):1463–72.PubMedCrossRefGoogle Scholar
  42. 42.
    •• Gold RKL, Bar-Or A, Arnold D, Giovannoni G, Selmaj K, Yang M, et al. Oral presentation 95 in Abstracts of the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. October 19–22, 2011. Amsterdam, The Netherlands. Mult Scler. 2011;17(10 Suppl):S9–524. Key data are presented on a phase 3 trial of dimethyl fumarate. The full data are expected to be published shortly. Efficacy and safety appear more promising than previously suspected.CrossRefGoogle Scholar
  43. 43.
    MacManus DG, Miller DH, Kappos L, Gold R, Havrdova E, Limmroth V, et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J Neurol. 2011;258(3):449–56.PubMedCrossRefGoogle Scholar
  44. 44.
    • Selmaj KGR, Kappos L, Bar-Or A, Arnold DL, Giovannoni G, Sweetser M, Novas M, Raghupathi K, Sheikh SI, Dawson KT. Poster 994 Safety and Tolerability of BG-12 in the Phase 3 DEFINE Trial in Patients with Relapsing-Remitting Multiple Sclerosis. 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis October 19–22, 2011 [serial on the Internet]. accessed 28 Feb 2012. Key data are presented on a phase 3 trial of dimethyl fumarate. The full data are expected to be published shortly. Efficacy and safety appear more promising than previously suspected.
  45. 45.
    Zamboni P, Galeotti R, Menegatti E, Malagoni AM, Tacconi G, Dall’Ara S, et al. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009;80(4):392–9.PubMedCrossRefGoogle Scholar
  46. 46.
    •• D’Haeseleer M, Cambron M, Vanopdenbosch L, De Keyser J. Vascular aspects of multiple sclerosis. Lancet Neurol. 2011;10(7):657–66. This is a comprehensive discussion of the vascular aspects of multiple sclerosis and evidence to assist in discussion with patients regarding unproven interventions.PubMedCrossRefGoogle Scholar
  47. 47.
    Reekers JA, Lee MJ, Belli AM, Barkhof F. Cardiovascular and Interventional Radiological Society of Europe commentary on the treatment of chronic cerebrospinal venous insufficiency. Cardiovasc Intervent Radiol. 2011;34(1):1–2.PubMedCrossRefGoogle Scholar
  48. 48.
    Thompson AJ, Toosy AT, Ciccarelli O. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol. 2010;9(12):1182–99.PubMedCrossRefGoogle Scholar
  49. 49.
    • Hartung HP, Montalban X, Sorensen PS, Vermersch P, Olsson T. Principles of a new treatment algorithm in multiple sclerosis. Expert Rev Neurother. 2011;11(3):351–62. This article shares a view on the next phase of developing treatment algorithms in an increasingly complex treatment environment.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Concord Repatriation General HospitalBurwoodAustralia

Personalised recommendations